Wugen: $115 Million Raised To Advance CAR-T For T-Cell Cancers
By Amit Chowdhry ● Sep 4, 2025
Wugen, a clinical-stage biotechnology company based in St. Louis, has announced the closing of a $115 million equity financing round. The investment, led by Fidelity Management & Research Company and joined by a consortium of life sciences investors including RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, and Aisling Capital Management, marks a pivotal moment in Wugen’s journey to bring its innovative CAR-T cell therapy to patients battling aggressive T-cell malignancies.